The Ewing, N.J., company said Wednesday it lost $5 million, or 4 cents per share, in the three months that ended Dec. 31. That compares to a loss of $154,000, or less than 1 cent per share, in the final quarter of 2011, when it had fewer shares outstanding. Revenue climbed about 1 percent to $5.5 million.

Analysts expected, on average, a loss of 3 cents per share on $5.3 million in revenue, according to FactSet.

The company's operating expenses more than doubled to $8.8 million in the quarter. That included a $2 million filing fee the company paid in connection with the new drug application it submitted to the Food and Drug Administration.

Antares has said the FDA intends to complete its review and make a decision on whether to approve the treatment by Oct. 14.

For the full year, Antares lost $11.4 million, or 10 cents per share, on $22.6 million in revenue.

The company said it ended the year with $85.2 million in cash and investments and no debt.